Rechercher des projets européens

Plus de 40 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS (LIVERHOPE)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,

Liver cirrhosis is a very common chronic disease and one of the leading causes of death in European. Moreover, cirrhosis has a marked impact in patients quality of life and represents a major burden for health systems. Treatment of cirrhosis is currently based on symptomatic management of complications and has not changed substantially in the last 20 years. There is an unmet need for therapies tha ...
Voir le projet

 18

 TERMINÉ 

GALAXY: Gut-and-liver axis in alcoholic liver fibrosis (GALAXY)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2021,

Alcohol overuse is an important societal challenge with annual healthcare costs of over €22 billion in Europe. Alcohol is the main cause of liver cirrhosis, which is the 5th and 7th most common cause of life years lost in respectively Eastern and Western Europe. Cirrhosis is considered irreversible but its precursor, liver fibrosis, is reversible when detected before disease progression. GALAXY pr ...
Voir le projet

 12

 TERMINÉ 

RECAP: Research on European Children and Adults born Preterm (RECAP)

Date du début: 1 janv. 2017, Date de fin: 31 mars 2021,

The project’s overall aim is to improve the health, development and quality of life of children and adults born very preterm (VPT, < 32 weeks of gestation) or very low birth weight (VLBW, < 1500g) – approximately 50 000 births each year in Europe – by establishing an ICT platform to integrate, harmonise and exploit the wealth of data from 20 European cohorts of VPT/VLBW children and adults and the ...
Voir le projet

 21

 TERMINÉ 

Children’s Liver Tumour European Research Network (ChiLTERN)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,

Liver cancer in the paediatric population is rare with an incidence approximately 1-1.5 per million population. The commonest tumour seen in the childhood population is hepatoblastoma (HB), usually seen in young children and infants. Much rarer (about 10% of paediatric liver cancers) is hepatocellular carcinoma (HCC), usually seen in the teenage population and sometimes associated with underlying ...
Voir le projet

 21

 TERMINÉ 

Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders (COSYN)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,

COSYN integrates outstanding European academic and three large Pharma to exploit genomic findings for intellectual disability (ID), autism, and schizophrenia. We capitalise on comorbidity, from clinic to cells and synapses, and have access to large existing samples. We focus on rare genetic variants of strong effect in patients with clinical comorbidity. Our aims are: (1) Understand comorbidity by ...
Voir le projet

 14

 TERMINÉ 

Training, Research and Raising of Public Awareness in Cell Biology and Pathology of Neuroglia (EU-GliaPhD)

Date du début: 1 déc. 2016, Date de fin: 30 nov. 2020,

The research in which the young scientists of the EU-GliaPhD consortium will be trained is centred on the role of neuron-glia interactions in brain function and pathology.Prompted by exciting discoveries of recent years, many academic research groups are currently focussing their research on the field of neuron-glia interactions for a better understanding of brain function. Also the private sector ...
Voir le projet

 13

 TERMINÉ 

Nodding Syndrome: a trans-disciplinary approach to identify the cause and decrease the incidence of river epilepsy (NSETHIO)

Date du début: 1 oct. 2015, Date de fin: 30 sept. 2020,

Nodding syndrome (NS) is a neurological, incurable syndrome, currently affecting mainly children between 5 and 15 years of age in South Sudan, Uganda and Tanzania. Since 1950, when NS was first described, its cause has remained a mystery. NS is characterized by head-nodding (an atonic form of epilepsy), often followed by clonic - tonic seizures, developmental retardation and faltering growth. In t ...
Voir le projet

 3

 TERMINÉ 

RELapses prevENTion in chronic autoimmune disease: common mechanisms and co-morbidities (RELENT)

Date du début: 1 nov. 2015, Date de fin: 30 avr. 2020,

RELENT is multidisciplinary group of scientists and clinical investigators whose goal is to develop individualized treatment for chronic autoimmune diseases, such as rheumatoid arthritis and vasculitis, that cause considerable mortality and morbidity, both from uncontrolled disease and treatment associated co-morbidities, like infection and malignancy. This requires the need to stratify patients b ...
Voir le projet

 14

 TERMINÉ 

Clinical development of a dendritic-cell vaccine therapy for acute myeloid leukaemia (AML-VACCiN)

Date du début: 1 janv. 2016, Date de fin: 31 mars 2020,

Eradicating minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML) is an area of high unmet medical need. AML is a deadly rare disease that affects both children and adults. Approximately 45% of younger AML patients who are treated will be cured, and in older patients (>60 years of age), 85% will relapse and die within 2 years.Immunotherapy has great potential for treating M ...
Voir le projet

 12

 TERMINÉ 

Zoonotic Anticipation and Preparedness Initiative (ZAPI)

Date du début: 1 mars 2015, Date de fin: 29 févr. 2020,

Emerging infectious diseases are occurring at increasing frequency in Europe and other regions of the world, having profound impacts on public and/or veterinary health as well as disruptive effects on sector, regional or even global economy. The predominantly zoonotic nature of emerging pathogens calls for a One Health approach uniting the human medical and veterinary fields, dedicated to swiftly ...
Voir le projet

 21

 TERMINÉ 

COllaborative Management Platform for detection and Analyses of (Re-)emerging and foodborne outbreaks in Europe (COMPARE)

Date du début: 1 déc. 2014, Date de fin: 30 nov. 2019,

COMPARE aims to harness the rapid advances in molecular technology to improve identification and mitigation of emerging infectious diseases and foodborne outbreaks. To this purpose COMPARE will establish a “One serves all” analytical framework and data exchange platform that will allow real time analysis and interpretation of sequence-based pathogen data in combination with associated data (e.g. c ...
Voir le projet

 32

 TERMINÉ 

Activation and Regulation of the NLRP3 Inflammasome (InflammAct)

Date du début: 1 juil. 2014, Date de fin: 30 juin 2019,

The innate immune system protects the host from infections, detects and repairs tissue damage and functions to maintain tissue homeostasis. Several families of signaling receptors can recognize microbial substances or altered host molecules and orchestrate a coordinated inflammatory response. Inflammasomes are signaling platforms that control proteolytic activation of highly proinflammatory cytoki ...
Voir le projet

 1

 TERMINÉ 

European Virus Archive goes global (EVAg)

Date du début: 1 avr. 2015, Date de fin: 31 mars 2019,

The overall objective will be to create and mobilise an International network of high calibre centres around a strong European group of institutes selected for their appropriate expertises, to collect, amplify, characterise, standardise, authenticate, distribute and track, mammalian and other exotic viruses. The network of EVAg laboratories including 25 institutions represents an extensive range o ...
Voir le projet

 27

 TERMINÉ 

The other side of optogenetics: multicolored genetically encoded hybrid voltage sensors (GEVOS) for ultrafast membrane potential measurements in cortical microcircuits (MULTIGEVOS)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,

"Optogenetics are used to activate or silence specific sets of neurons, intracellular signaling pathways, or to examine brain structure at an unprecedented detail. The only optogenetic approach lagging behind all others is the genetically encoded optical monitoring of multi-neuronal activity at a time resolution of single action potentials. Such ultrafast (
Voir le projet

 1

 TERMINÉ 

Platform foR European Preparedness Against (Re-)emerging Epidemics (PREPARE)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,

Far from receding, the threats posed by infections with epidemic potential grow ever greater. Although Europe has amongst the best healthcare systems in the world, and also the world’s supreme researchers in this field, we lack co-ordination and linkage between networks that is required to respond fast to new threats. This consortium of consortia will streamline our response, using primary and sec ...
Voir le projet

 27

 TERMINÉ 

Aetionomy – Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of Drug Development and Therapy (AETIONOMY)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2018,

IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this call, we propose (I) the development of a generic AETIONOMY pipeline to capture and infer over mechanistic knowledge of pathophysiology, and (II) the focused application of this pipeline to derive clinically significant mechanistic taxonomies of neurodegenerativ ...
Voir le projet

 20

 TERMINÉ 

POLY-stakeholders for integrated CARE for chronic patients in acute phases (POLYCARE)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2018,

Nowadays, chronic diseases and co-morbidities have to be managed during a long period of time among health and social care systems, thus a big amount of budget and resources should be destined to them. If these patients could stay at home during their illnesses exacerbations, a big amount of resources could be saved, a more independent like and a higher quality of life for these patients could be ...
Voir le projet

 8

 TERMINÉ 

Neuropathic pain: biomarkers and druggable targets within the endogenous analgesia system (NEUROPAIN)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2018,

Neuropathic pain has a high incidence in Europe and often affects the patient’s emotional balance and quality of life. Recent meta-analyses have shown that conventional analgesic drugs are not sufficiently effective in these patients and are limited by serious side effects. The search for new analgesics is extremely difficult despite identification of several new potential targets and enormous inv ...
Voir le projet

 12

 TERMINÉ 

Targets and biomarkers for antiepileptogenesis (EPITARGET)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Epilepsy is a devastating condition affecting over 50 million people worldwide. This multidisciplinary project is focused on the process leading to epilepsy, epileptogenesis, in adults. Our main hypothesis is that there are combinations of various causes, acting in parallel and/or in succession, that lead to epileptogenesis and development of seizures. Our central premise and vision is that a comb ...
Voir le projet

 20

 TERMINÉ 

PanCare Studies in Fertility and Ototoxicity to Improve Quality of Life after Cancer during Childhood, Adolescence and Young Adulthood (PANCARELIFE)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Survival rates after childhood cancer now reach nearly 80% in developed European countries as a result of more effective therapies and better supportive care, leading to a steady increase in the number of survivors in the population. However, the treatments that have improved survival are harsh and cause serious side-effects that can greatly impact survivors’ quality of life in the long term. The ...
Voir le projet

 19

 TERMINÉ 

Consortium on Organ Preservation in Europe (COPE)

Date du début: 1 janv. 2013, Date de fin: 30 juin 2018,

The discrepancy between organ supply and demand remains the biggest challenge facing the transplant community today. In order to increase the amount of available donor organs, transplant specialists are increasingly turning to sub-optimal donor organs. Organs from such donors, usually have normal or near normal function before death, but retrieval, storage and transplantation cause progressive inj ...
Voir le projet

 16

 TERMINÉ 

European stem cell consortium for neural cell replacement, reprogramming and functional brain repair (Neurostemcellrepair)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

Neurostemcellrepair aims at taking human stem cells through the final steps toward clinical application in cell replacement therapy for neurological disorders. PD will be taken as the prototypical disease because stem cell therapy is now close to clinical translation. Moreover, we will tackle next generation issues pertaining to stem cells at a basic level and develop new approaches and novel cell ...
Voir le projet

 13

 TERMINÉ 

Open Project for the European Radiation Research Area (OPERRA)

Date du début: 1 juin 2013, Date de fin: 31 mai 2017,

"Within the OPERRA project, it is proposed that the MELODI Association, as a well-advanced network, takes the lead in establishing the necessary structures able to manage the long-term European research programmes in radiation protection, also taking advantage of the valuable experience gathered through the DoReMi network of excellence. Whilst in fields adjacent to low-dose risk research (radioeco ...
Voir le projet

 71

 TERMINÉ 

Imaging of Neuroinflammation in Neurodegenerative Diseases (INMiND)

Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,

The goal of this proposal (INMiND) is to carry out collaborative research on molecular mechanisms that link neuroinflammation with neurodegeneration in order to identify novel biological targets for activated microglia, which may serve for both diagnostic and therapeutic purposes, and to translate this knowledge into the clinic. The general objectives of INMiND are:(i) to identify novel mechanisms ...
Voir le projet

 32

 TERMINÉ 

Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk (ABIRISK)

Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,

The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Voir le projet

 39

 TERMINÉ 

Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,

The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test sys ...
Voir le projet

 29

 TERMINÉ 

European Bank for induced pluripotent Stem Cells (EBISC)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2016,

EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services. Its goal is to demonstrate an operational banking and distribution service of iPSC lines after 3 years and to establish subsequently for Europe a centralised, not-for-profit bank providing all qualified users with access to scalable, cos ...
Voir le projet

 30

 TERMINÉ 

ANTIcipating the Global Onset of Novel Epidemics (ANTIGONE)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2016,

In recent years, an increased number of zoonotic viruses and bacteria have crossed the species barrier to humans and caused or threatened to cause human pandemics with high morbidity and mortality. Because of our inability to predict the emergence of these pathogens, it is difficult to take preventive measures. It is known that zoonotic pathogens need to cross barriers at the animal-human interfac ...
Voir le projet

 14

 TERMINÉ 

Patient-centered palliative care pathways in advanced cancer and chronic disease (INSUP-C)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,

Integrated delivery systems of care, e.g. networks of health organizations and professionals who work together to coordinate services to meet their patients’ needs, are an important way of linking fragmented services and maximizing system efficiency and seamlessness of patient transition. Research increasingly shows that patients with advanced cancer and advanced chronic disease are treated well ...
Voir le projet

 11

 TERMINÉ 

Biopharmaceutical therapy for treatment of Primary Hyperoxaluria (ELIMOX)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2016,

"Interest in the use of naturally occurring human gut bacteria as pharmaceutical drugs has increased as knowledge about the human microbiota and its role in health and disease has advanced.The ELIMOX project proposes to develop a new drug from Oxalobacter formigenes, an anaerobic bacterium whose only carbon source is oxalate, for the treatment of primary hyperoxaluria (PH). PH is a rare and life-t ...
Voir le projet

 12

 TERMINÉ 

Quantitative Large Scale Proteomics of Lysosomal Storage Disease (Storage Proteomics)

Date du début: 1 août 2012, Date de fin: 31 juil. 2016,

Lysosomal storage diseases (LSD) are a group of ~ 50 genetic disorders, which mainly affect children. LSDs are clinically heterogeneous but are frequently dominated by progressive neurologic deterioration. Most patients pass away after years of lingering illness. In general, the molecular pathogenesis of LSDs is still poorly understood. To gain insight into disease mechanisms the project investiga ...
Voir le projet

 1

 TERMINÉ 

ASSET: Analysing and Striking the Sensitivities of Embryonal Tumours (ASSET)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2016,

Cancer is hallmarked by multiple genetic aberrations that lead to a functional derangement of cellular signalling networks. Embryonal tumours (ETs) comprising neuroblastoma, medulloblastoma and Ewing sarcoma, occur early in life, and thus may reveal pathogenetically relevant lesions clearer than adulthood tumours which carry passenger mutations accumulated during life. ASSET will exploit this fact ...
Voir le projet

 20

 TERMINÉ 

Integrating chemical approaches to treat pancreatic cancer: making new leads for a cure (Panacreas)

Date du début: 1 mars 2011, Date de fin: 29 févr. 2016,

Pancreatic ductal adenocarcinoma (PDAC) causes 34000 deaths in the EU every year. Conventional cancer treatments have close to no impact on this disease. As a result, almost all patients diagnosed with PDAC develop metastases and eventually die. Given this poor outlook, the search for new therapeutics is mandatory. These will have to target relevant cancer pathways and be designed based on the ava ...
Voir le projet

 12

 TERMINÉ 

Stem Cells for Relevant Efficient Extended and Normalized Toxicology (SCR&TOX)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,

In the development of products for use by humans it is vital to identify compounds with toxic properties at an early stage of their development, to avoid spending time and resource on unsuitable and potentially unsafe candidate products. Human pluripotent stem cell lines offer a unique opportunity to develop a wide variety of human cell-based test systems because they may be expanded indefinitely ...
Voir le projet

 16

 TERMINÉ 

European Network of HIV/AIDS Cohort Studies to Coordinate at European and International Level Clinical Research on HIV/AIDS (EuroCoord)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,

Over the past 15 years, EU-funded cohorts and collaborations (EuroSIDA, CASCADE and PENTA), have played a central role in developing our understanding of HIV progression and the effects of ART, enabling European expertise to contribute directly to the advances in patient diagnosis and management worldwide, and providing a continued surveillance mechanism for detection of emerging problems at a Eur ...
Voir le projet

 26

 TERMINÉ 

Epilepsy Pharmacogenomics: delivering biomarkers for clinical use (EpiPGX)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,

The purpose of the project is to identify genome-based biomarkers for use in clinical practice to individualise treatment of epilepsy, and stratify patients for clinical trials, aiming to avoid chronicity, prevent relapse and reduce adverse drug reactions (ADRs).The need for improved treatments in epilepsy is undoubted. Epilepsy is affects 50,000,000 people of all ages worldwide. Epilepsy is serio ...
Voir le projet

 15

 TERMINÉ 

KRAB zinc finger gene biology in evolution and disease (KRAB-ZNF)

Date du début: 1 juil. 2011, Date de fin: 30 juin 2015,

The „KRAB-ZNF“ initiative is driven by recent observations that KRAB-ZNF genes, an evolutionarily conserved gene family of more than 350 transcriptional repressors encoded in the human genome, are predominantly expressed in testis and fetal brain. To elucidate functions of KRAB ZNF genes in evolution and diseases, experts in KRAB ZNF gene biology (B1/P1), proteomics (B1/P2), systems biology and ag ...
Voir le projet

 4

 TERMINÉ 

Infectious triggers of chronic autoimmunity (INTRICATE)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2015,

This proposal builds on existing expertise and collaborations of a multidisciplinary Consortium of basic scientists and clinical investigators each of whom has made a substantial individual contribution to understanding the links between infection and autoimmunity. The aim of the INTRICATE Consortium is to prosecute a programme of Translational Research that deliniates the role of infection in the ...
Voir le projet

 13

 TERMINÉ 

THERAPEUTIC AND PREVENTIVE IMPACT OF NUTRITIONAL LIPIDS ON NEURONAL AND COGNITIVE PERFORMANCE IN AGING, ALZHEIMER’S DISEASE AND VASCULAR DEMENTIA (LIPIDIDIET)

Date du début: 1 août 2008, Date de fin: 31 mars 2015,

Major objective: It is our aim to develop a lipid based diet that is able to delay or prevent onset of Alzheimer’s disease and related diseases and has a stabilizing effect on cognitive performance in aging. Multiple lines of evidence suggest that there is a large overlap between risk factor of these three diseases. Importantly, there is equally strong evidence that prevention and treatment of the ...
Voir le projet

 19

 TERMINÉ 

Helminth-induced regulatory mechanisms that prevent the onset of diabetes (HELMINTH & DIABETES)

Date du début: 1 avr. 2011, Date de fin: 31 mars 2015,

In Europe >33 million people suffer from diabetes, a chronic disease associated with long-term pathology representing one of the biggest cost factors for the health care system. The ultimate goal of this proposal is to develop a novel immunomodulatory diabetes therapy by identifying parasitic worm (helminth) regulatory mechanisms which protect against autoimmune diseases. The applicants’ previous ...
Voir le projet

 1